Impact of body size descriptors on initial treatment response and thirty-day mortality in patients with gram-negative infections

Journal of Applied Research

Volumn 12, Issue 1, 2012, Pages 30-37

  Jeffres, Meghan N ^a,b,c   Barclay, Sean M ^a,b,c   Daly, Michael W ^d   Decerbo, Mark C ^a,b,c   Golenia, Peter ^e  

^a ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b University Medical Center of Southern Nevada   (United States)

^c University of Nevada School of Medicine   (United States)

^d ST LOUIS COLLEGE OF PHARMACY   (United States)

^e BOSTON MEDICAL CENTER   (United States)

Author keywords

Body mass index; Infection; Obesity; Weight

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BODY SIZE; BODY SURFACE; BODY WEIGHT; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; LEAN BODY WEIGHT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

EID: 84861751783     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. WHO. Obesity and overweight. World Health Organization; 2011 [updated March 2011; cited 2011 September 16, 2011]; Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
2. Huttunen R, Laine J, Lumio J, Vuento R, Syrjanen J. Obesity and smoking are factors associated with poor prognosis in patients with bacteraemia. BMC Infect Das. 2007;7:13.
3. Bochicchio GV, Joshi M, Bochicchio K, Tracy K, Scalea TM. A time-dependent analysis of intensive care unit pneumonia in trauma patients. J Trauma. 2004 Feb;56(2):296-301; discussion -3.
4. El-Solh A, Sikka P, Bozkanat E, Jaafar W, Davies J. Morbid obesity in the medical ICU. Chest. 2001 Dec;120(6):1989-97.
5. Carratala J, Roson B, Femandez-Sabe N, Shaw E, del Rio O, Rivera A, et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis. 2003 Mar;22(3):151-7.
6. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818-29.
7. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Oh MD, et al. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clrn Infect Dis. 2004 Sep 15;39(6):812-8.
8. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002 Ju1;122(1):262-8.
9. Falagas ME, Athanasoulia AP, Peppas G, Kara-georgopoulos DE. Effect of body mass index on the outcome of infections: a systematic review. Obes Rev. 2009 May;10(3):280-9.
10. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1-10.
11. Tam VH GE, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008;46:862-7.
12. Lorente L, Jimenez A, Martin MM, Iribarren JL, Jimenez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/ tazobactam administered by continuous or intermittent infusion. Int JAntimicrob Agents. 2009 May;33(5):464-8.
13. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006 Feb;40(2):219-23.
14. Burkhardt O, Brunner M, Schmidt S, Grant M, Tang Y, Derendorf H. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. JAntimicrob Chemother. 2006 Sep;58(3):632-6.
15. Chiba K, Tsuchiya M, Kato J, Ochi K, Kawa Z, Ishizaki T. Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers. Antimicrob Agents Chemother. 1989 Aug;33(8):1188-92.
16. Yost RL, Derendorf H. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit. 1986;8(2):189-94.
17. Mann HJ, Buchwald H. Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients. Drug Intell Clin Pharm. 1986 Nov;20(11):869-73.
18. Lovering AM, Walsh TR, Bannister GC, Mac-Gowan AP. The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone. J Antimiciob Chemother. 2001 Apr;47(4):483-6.
19. Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery. 1989 Oct;106(4):750-6; discussion 6-7.